VEXIM Secures a Contingent Equity Line PACEO® with SOCIETE GENERALE Business Wire TOULOUSE, France -- October 30, 2013 Regulatory News : Vexim S. A. (Paris:ALVXM) (FR0011072602 - ALVXM), a medical device company specialized in minimally-invasive solutions for the treatment of vertebral fractures, announces that it has negotiated a contingent equity line with SOCIETE GENERALE, exercisable by tranches at VEXIM’s discretion, as authorized by the Shareholders’ Meeting of June 18, 2013. This optional equity financing will allow VEXIM, to broaden its financial flexibility in order to continue its strong commercial development, while diversifying its financial tools and minimizing dilution for its shareholders. At VEXIM’s request, SOCIETE GENERALE is committed to subscribe to successive capital increases over the next 24 months, within the global limit of 450,000 shares, being 9.8% of the 4,590,645 shares currently outstanding. Should the entire contingent equity line be drawn down by the emission of 450000 new shares, a shareholder who currently owns 1% of the company’s share capital would see his or her share ownership reduced to 0.91%. For each emission of shares, the issue price will depend on the average market share price discounted by no more than 8%. This discount will enable SOCIETE GENERALE, as a financial intermediary with no intention of remaining shareholder in the company, to underwrite the subscription, regardless of capital market volatility. VEXIM has no minimum drawdown obligation, and only intends to use this facility if market conditions allow financing that it is in the best interest of both the Company and its shareholders. *** Next press release: *2013 annual sales: January 2014 *2013 annual results: March 2014 About Vexim, the innovative back microsurgery specialist Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital^1 and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Turkey, Argentina, India, Taiwan and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3^rd 2012. For further information, please go to www.vexim.com SpineJack®^2, a revolutionary implant for treating Vertebral Compression Fractures The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029. *Name: VEXIM *ISIN code: FR0011072602 *Ticker: ALVXM ^1 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr. ^2 This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use. Contact: VEXIM Vincent Gardès, Tel: +33 5 61 48 48 38 CEO email@example.com or NewCap. Financial Communications and Investor Relations Dusan Oresansky / Emmanuel Huynh Tel: +33 1 44 71 94 92 firstname.lastname@example.org or Alize RP Press Relations Caroline Carmagnol, Tel: +33 6 64 18 99 59 email@example.com or Christian Berg, Tel: +33 1 70 22 53 86 firstname.lastname@example.org
VEXIM Secures a Contingent Equity Line PACEO® with SOCIETE GENERALE
Press spacebar to pause and continue. Press esc to stop.